The Mayo Clinic Cancer Center (MCCC) provides oversight for the scientific aspects and performance of cancer interventional clinical trials conducted at Mayo Clinic through the Center's Protocol Review and Monitoring System (PRMS). The focus of the PRMS is on scientific merit, priorities, and progress of the clinical research protocols conducted at the MCCC. The Scientific Review Committee (SRC) uses a consistent and defined process for scientific review that is achieved through established written review criteria, common reporting forms, and defined expectations. The SRC has responsibility for the approval and/or disapproval of each study, as well as for the final decision concerning prioritization. To accommodate the increasing complexity and volume of trials, 4 SRC subcommittees cover trials in hematology and solid tumors with drug- predominant therapy, radiation-predominant therapy, and surgery-predominant therapy, respectively. Another subcommittee of the SRC, the Scientific Progress Review Subcommittee (SPRC), reviews modifications and amendments for approved and active studies. If the modification or amendment proposes significant changes to the scientific components of a trial, SPRC may request that the SRC review the change and determine if it is appropriate for the trial to remain active and for the modification or amendment to be implemented. SPRC also monitors accrual to interventional trials to ensure adequate scientific progress. If accrual is not adequate, SPRC will initially work with the investigator to determine the reasons. If progress is not made and there is no reasonable expectation that changes will occur, SPRC forwards the study to SRC for consideration of closure. The MCCC PRMS is under the governance of the MCCC Clinical Research Committee, which is chaired by the Deputy Director for Clinical Research. The Clinical Research Committee reviews and approves the leadership and membership of each SRC subcommittee at least annually. It also provides guidance on standard scientific review and administrative processes for SRC and SPRC and reviews the metrics from these committees quarterly.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8

Showing the most recent 10 out of 1129 publications